Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study

Florian Kurth, Michel Develoux, Matthieu Mechain, Jan Clerinx, Spinello Antinori, Ida E Gjørup, Joaquím Gascon, Kristine Mørch, Emanuele Nicastri, Michael Ramharter, Alessandro Bartoloni, Leo Visser, Thierry Rolling, Philipp Zanger, Guido Calleri, Joaquín Salas-Coronas, Henrik Nielsen, Gudrun Just-Nübling, Andreas Neumayr, Anna HachfeldMatthias L Schmid, Pietro Antonini, Peter Pongratz, Peter Kern, José Saraiva da Cunha, Antoni Soriano-Arandes, Mirjam Schunk, Norbert Suttorp, Christoph Hatz, Thomas Zoller, TropNet Severe Malaria Investigator Group

33 Citationer (Scopus)

Abstrakt

Intravenous artesunate improves survival in severe malaria, but clinical trial data from nonendemic countries are scarce. The TropNet severe malaria database was analyzed to compare outcomes of artesunate vs quinine treatment. Artesunate reduced parasite clearance time and duration of intensive care unit and hospital treatment in European patients with imported severe malaria.
OriginalsprogEngelsk
TidsskriftClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Vol/bind61
Udgave nummer9
Sider (fra-til)1441-4
Antal sider4
ISSN1058-4838
DOI
StatusUdgivet - 1 nov. 2015

Fingeraftryk

Dyk ned i forskningsemnerne om 'Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study'. Sammen danner de et unikt fingeraftryk.

Citationsformater